Payment overview · 2025
General Payments
$480.76
24 reported records · 10 companies
Healthcare provider profile · identity verified
Willus Mark Horne, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · LAUREL, MS · NPI 1417961012
Verified facts
What the public records show
CMS Open Payments records show Willus Mark Horne, M.D. received $480.76 in general payments during 2025 across 24 reported records.
Abbott Laboratories accounted for 35.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Ozempic.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 385 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 158 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 285 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Abbott Laboratories | Unresolved — no canonical attribution shown | $168.56 | 35.1% | 9 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $92.28 | 19.2% | 4 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $64.02 | 13.3% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $34.12 | 7.1% | 2 | 2025 |
| Tandem Diabetes Care, Inc. | Unresolved — no canonical attribution shown | $31.22 | 6.5% | 1 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $22.07 | 4.6% | 1 | 2025 |
| Averitas Pharma Inc. | Unresolved — no canonical attribution shown | $21.48 | 4.5% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $17.29 | 3.6% | 1 | 2025 |
| Sequel Med Tech, LLC | Unresolved — no canonical attribution shown | $15.89 | 3.3% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $13.83 | 2.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $448.49 | 23 |
| Education | $32.27 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FREESTYLE LIBRE Normalized: freestyle libre |
Device | Abbott Laboratories | $168.56 | 9 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $64.02 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $39.11 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $34.12 | 2 | 2025 |
Source payment records
|
|||||
| t:slim X2 Insulin Pump with Control-IQ Normalized: t slim x2 insulin pump with control iq |
Device | Tandem Diabetes Care, Inc. | $31.22 | 1 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $22.07 | 1 | 2025 |
Source payment records
|
|||||
| QUTENZA Normalized: qutenza |
Drug | Averitas Pharma Inc. | $21.48 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $17.29 | 1 | 2025 |
Source payment records
|
|||||
| TWIIST Normalized: twiist |
Device | Sequel Med Tech, LLC | $15.89 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $13.83 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 385 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 285 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
40 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
385 | 119 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
158 | 46 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
58 | 17 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
285 | 102 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 479 | 154 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 394 | 132 |
| Jardiance | Empagliflozin | 385 | 119 |
| Atorvastatin Calcium | Atorvastatin Calcium | 317 | 109 |
| Losartan Potassium | Losartan Potassium | 308 | 107 |
| Ozempic | Semaglutide | 285 | 102 |
| Levothyroxine Sodium | Levothyroxine Sodium | 273 | 90 |
| Potassium Chloride | Potassium Chloride | 269 | 83 |
| Metformin Hcl Er | Metformin Hcl | 259 | 100 |
| Gabapentin | Gabapentin | 250 | 78 |
| Metformin Hcl | Metformin Hcl | 239 | 82 |
| Farxiga | Dapagliflozin Propanediol | 221 | 91 |
| Pantoprazole Sodium | Pantoprazole Sodium | 221 | 78 |
| Omeprazole | Omeprazole | 215 | 67 |
| Hydrochlorothiazide | Hydrochlorothiazide | 212 | 65 |
| Lisinopril | Lisinopril | 183 | 60 |
| Metoprolol Succinate | Metoprolol Succinate | 167 | 55 |
| Mounjaro | Tirzepatide | 158 | 46 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 151 | 58 |
| Pravastatin Sodium | Pravastatin Sodium | 146 | 48 |
| Montelukast Sodium | Montelukast Sodium | 142 | 46 |
| Furosemide | Furosemide | 134 | 49 |
| Tamsulosin Hcl | Tamsulosin Hcl | 127 | 44 |
| Allopurinol | Allopurinol | 107 | 32 |
| Eliquis | Apixaban | 105 | 31 |
| Novolog Flexpen | Insulin Aspart | 103 | 38 |
| Clopidogrel | Clopidogrel Bisulfate | 100 | 33 |
| Famotidine | Famotidine | 96 | 37 |
| Duloxetine Hcl | Duloxetine Hcl | 94 | 32 |
| Carvedilol | Carvedilol | 92 | 35 |
| Trazodone Hcl | Trazodone Hcl | 90 | 35 |
| Pregabalin | Pregabalin | 86 | 27 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 85 | 17 |
| Simvastatin | Simvastatin | 83 | 27 |
| Spironolactone | Spironolactone | 83 | 27 |
| Ezetimibe | Ezetimibe | 79 | 26 |
| Ibandronate Sodium | Ibandronate Sodium | 74 | 26 |
| Citalopram Hbr | Citalopram Hydrobromide | 73 | 20 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 70 | 17 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 65 | 28 |
| Escitalopram Oxalate | Escitalopram Oxalate | 63 | 26 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 63 | 18 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 62 | 19 |
| Oxycodone Hcl | Oxycodone Hcl | 62 | suppressed |
| Myrbetriq | Mirabegron | 60 | 17 |
| Sertraline Hcl | Sertraline Hcl | 58 | 16 |
| Trulicity | Dulaglutide | 58 | 17 |
| Pioglitazone Hcl | Pioglitazone Hcl | 57 | 24 |
| Clonidine Hcl | Clonidine Hcl | 56 | 16 |
| Tresiba Flextouch U-100 | Insulin Degludec | 55 | 19 |
| Glimepiride | Glimepiride | 53 | 20 |
| Valsartan | Valsartan | 53 | 16 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 51 | 18 |
| Tramadol Hcl | Tramadol Hcl | 50 | 20 |
| Fluoxetine Hcl | Fluoxetine Hcl | 49 | 18 |
| Mirtazapine | Mirtazapine | 49 | 13 |
| Finasteride | Finasteride | 48 | 12 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 47 | 20 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 46 | 17 |
| Meloxicam | Meloxicam | 46 | 20 |
| Ropinirole Hcl | Ropinirole Hcl | 46 | 21 |
| Fluticasone Propionate | Fluticasone Propionate | 43 | 16 |
| Bupropion Xl | Bupropion Hcl | 41 | 12 |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 41 | 14 |
| Fenofibrate | Fenofibrate | 40 | 12 |
| Metoprolol Tartrate | Metoprolol Tartrate | 40 | 18 |
| Synthroid | Levothyroxine Sodium | 40 | 12 |
| Xarelto | Rivaroxaban | 40 | 13 |
| Tresiba Flextouch U-200 | Insulin Degludec | 39 | 14 |
| Zolpidem Tartrate | Zolpidem Tartrate | 39 | 11 |
| Buspirone Hcl | Buspirone Hcl | 38 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 37 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 37 | 16 |
| Alendronate Sodium | Alendronate Sodium | 36 | 11 |
| Warfarin Sodium | Warfarin Sodium | 36 | suppressed |
| Linzess | Linaclotide | 35 | 18 |
| Ondansetron Odt | Ondansetron | 33 | 11 |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 32 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 31 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 29 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 29 | 12 |
| Baclofen | Baclofen | 28 | suppressed |
| Entresto | Sacubitril/Valsartan | 28 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 28 | 12 |
| Januvia | Sitagliptin Phosphate | 28 | 12 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 27 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 26 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 26 | 12 |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 26 | suppressed |
| Alprazolam | Alprazolam | 25 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 25 | suppressed |
| Atenolol | Atenolol | 24 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 24 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 24 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 23 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 23 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 21 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 20 | suppressed |
| Indapamide | Indapamide | 20 | suppressed |
| Lactulose | Lactulose | 20 | suppressed |
| Rybelsus | Semaglutide | 20 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 19 | suppressed |
| Glipizide Er | Glipizide | 18 | suppressed |
| Ibuprofen | Ibuprofen | 18 | suppressed |
| Lidocaine | Lidocaine | 18 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 18 | 16 |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 18 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 18 | suppressed |
| Klor-Con M20 | Potassium Chloride | 17 | suppressed |
| Torsemide | Torsemide | 17 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 16 | 14 |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 16 | suppressed |
| Irbesartan | Irbesartan | 16 | suppressed |
| Lansoprazole | Lansoprazole | 16 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 16 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 16 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Celecoxib | Celecoxib | 15 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 15 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 15 | suppressed |
| Clonazepam | Clonazepam | 14 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 14 | suppressed |
| Tradjenta | Linagliptin | 14 | suppressed |
| Lorazepam | Lorazepam | 13 | suppressed |
| Repatha Syringe | Evolocumab | 13 | suppressed |
| Sucralfate | Sucralfate | 13 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 12 | suppressed |
| Diazepam | Diazepam | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 12 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Digoxin | Digoxin | 11 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 11 | suppressed |
| Primidone | Primidone | 11 | suppressed |
| Victoza 2-Pak | Liraglutide | 11 | suppressed |
| Victoza 3-Pak | Liraglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $480.76 · 24 records | Abbott Laboratories | FREESTYLE LIBRE, INSPIRE, JARDIANCE, Kerendia, Omnipod, Ozempic, QUTENZA, SPRAVATO, TWIIST, t:slim X2 Insulin Pump with Control-IQ | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Janssen Pharmaceuticals, Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error